Literature DB >> 27499790

Synthesis and cytotoxicity evaluation of some new 6-nitro derivatives of thiazole-containing 4-(3H)-quinazolinone.

Leila Hosseinzadeh1, Alireza Aliabadi2, Masoud Kalantari3, Abolfazl Mostafavi4, Marzieh Rahmani Khajouei2.   

Abstract

Quinazolinones are a group of fused heterocyclic compounds which have valuable biological properties including cytotoxic, antibacterial and antifungal activities. Thiazole group-containing compounds have been also reported to have a wide range of biological activities such as antitumor, anti-inflammatory, analgesic and antibacterial effects. Due to valuable cytotoxic effects of both thiazole groups and quinazoline derivatives, in this study a series of quinazolinone-thiazole hybrids were synthesized and evaluated for their cytotoxic effects on three cell lines including MCF-7, HT-29, and PC-3. Among tested compounds (quinazolinones and three intermediates), k5 and k6 showed highest cytotoxic activities against PC3 cell line. K6 and C were most active compounds against MCF7 and K6 showed best cytotoxicity on HT-29 cell line.

Entities:  

Keywords:  Cytotoxicity; Quinazolinone; Thiazole

Year:  2016        PMID: 27499790      PMCID: PMC4962301     

Source DB:  PubMed          Journal:  Res Pharm Sci        ISSN: 1735-5362


INTRODUCTION

Cancer is a major health problem in developing and undeveloped countries. Although major advances have been made in the treatment of this disease, due to the problems associated with drug resistance, the continued efforts to discover new anticancer agents is very important. To discover various chemical substances which may serve as leads to design new antitumor agents, we are mostly interested in this work with quinazoline derivatives, which are well known compounds as a new class of anticancer agents with significant therapeutic value against tumors (1). Quinazoline and their derivatives are building blocks for approximately 150 naturally occurring alkaloids isolated from a number of families of the plant kingdom, from microorganisms and animals (2). There are many reports about biological activities in synthetic and natural quinazolines including sedative (3), anticonvulsant(345), anti-inflammatory (36), antitumor (37), antibacterial (38910), antifungal (45), antitubercular (46811), antimalarial (912), antiviral (46), anti-HIV (3891013), and hypolipidemic activities (1415). Some drugs have been synthesized with quinazoline structure such as cloroqualone (antitussive), diproqualone (analgesic) (16), gefitinib, lapatinib (anticancer) (1), piriqualone (anti-convulsant) (17), doxazocin (antihypertensive) (18), prazosin (antihypertensive) (19), trimetrexate (antibacterial), thymitaq (anticancer) (20) and raltitrexed (anticancer) (21). Thiazole group containing compounds have been also reported to have a wide range of biological activities including: antitumor, anti-inflammatory, analgesic, antibacterial, and antifungal effects(22232425). Thiazole, an important heterocyclic ring, is widely used in anticancer drug development. Several anticancer agents containing thiazole moiety have been discovered, like bleomycin and tiazofurin. Ritonavir (anti-HIV), meloxicam (anti-inflammatory), nizatidine (anti-peptic ulcer) and penicillin (antibiotic) are some other examples of thiazole bearing products with biological activities (2226). Due to the valuable cytotoxic effects of both thiazole and quinazoline compounds, in this study, a series of quinazolinone-thiazole hybrids were synthesized. Furthermore, antiproliferative activity of derivatives was determined using tumor cells in culture against MCF-7, HT-29, and PC-3.

MATERIALS AND METHODS

Instrumentation

All starting materials, reagents and solvents were purchased from commercial suppliers like Merck (Germany) and Aldrich (USA) companies. The purity of the prepared compounds was proved by thin layer chromatography (TLC) using various solvents of different polarities. Merck silica gel 60 F254 plates were applied for analytical TLC. 1HNMR spectra were recorded using a (Bruker 400 MHz, Germany) spectrometer, and chemical shifts are expressed as δ (ppm) with tetramethylsilane (TMS) as internal standard. The IR spectra were obtained on a Shimadzu 470 spectrophotometer (potassium bromide disks). Melting points were determined using electrothermal melting point analyzer apparatus (IA 9000, UK) and are uncorrected. The mass spectra were run on a Finnigan TSQ-70 spectrometer (Finnigan, USA) at 70 eV. All cell lines were purchased from Pasteur Institute of Iran. To produce 6-nitroderivatives of thiazole-containing 4(3H) quinazolinones (K1-K6), the primary amine G was synthesized through a five-step procedure. In the first step, 4-phthalimido-2-butanone (compound B) (Fig. 1), was prepared through the addition of methyl vinyl ketone to phthalimide. In the second step, 1-bromo-4-N-phthalimido-2-butanone (compound C) (Fig. 1) was synthesized by bromination of the methyl group of compound B. Nucleophilic substitution of separately synthesized thiobenzamide (compound E) (Fig. 1) to the brominated intermediate compound C afforded 2-phenyl-4-[(2-N-phthalimido)ethyl]thiazole (compound F) (Fig. 1) which was reacted with hydrazine hydrate and deprotected to produce the 2-phenyl-4-(2-aminoethyl) thiazole (compound G) (Fig. 1). A group of benzoxazinones (J1-J6) with different substituent at position 2 were synthesized. The reaction of the primary amine (compound G) with these benzoxazinones yielded the final compounds as presented in Fig. 1.
Fig. 1

General reaction for preparation of the final compounds

General reaction for preparation of the final compounds

Cell culture conditions

PC3 (prostate carcinoma), MCF-7 (breast cancer), and HT-29(colon carcinoma) cells were maintained at 37 °C in a humidified atmosphere (90%) containing 5% CO2. PC3, MCF-7, and HT-29 cell lines were cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 5% v/v fetal bovine serum, 100 U/ml penicillin, and 100 mg/mL streptomycin. The medium was changed every two to three days and sub-cultured when the cell population density reached to 70–80% confluence. Cells were seeded at an appropriate density according to each experimental design (27).

Cytotoxicity assay

HT-29, MCF-7, and PC-3 cells were seeded in triplicate on 96-well tissue culture plates (15 × 103 cells/well) and incubated overnight. Cells were treated with different concentrations of the derivatives (0-275 μM) for 24 h. Then the medium was removed and the MTT substrate was prepared in a physiologically balanced solution (PBS), added to cells in culture, at a final concentration of 0.5 mg/ml, and incubated for 1 to 4 h. The formazan crystals were solubilized in dimethyl sulfoxide (DMSO) and the quantity of formazan (presumably directly proportional to the number of viable cells) was measured by recording changes in absorbance at 570 nm using a plate reading spectrophotometer. Cell viability was calculated using following formula: IC50 values were calculated by plotting the cell viability against compound concentrations (27).

RESULTS

Details of preparation procedures and chemistry of synthesized compounds

4-Phthalimido-2-butanone (B) To a well-stirred suspension of phthalimide (compound A) (Fig. 1) (36.75 g, 250 mmol) and 3-buten-2-one (17.5 g, 250 mmol) in 250 ml of ethyl acetate (EtOAc) was added a freshly prepared solution of sodium ethoxide (NaOEt) (0.67 g, 12 mmol) in 65 ml of anhydrous ethanol (EtOH) under an N2 atmosphere. After 2 h stirring at ambient temperature, the mixture was refluxed until an almost clear solution was obtained and refluxing was continued for an additional 2 h. After cooling, the solvent was removed in vacuo and the solid residue was crystallized from hot 96% EtOH to obtain compound B as a white powder (28). Yield:92%, m.p 112 °C, (Found: M217, C12H11NO3 requires 217), νmax = 3010, 2925, 1700 cm-1, 1HNMR (400 MHz, CDCl3) δ: 2.16 (3H, s, H-Ch), 2.85 (2H, t, J = 7.2 Hz, H-Cg), 3.93 (2H, t, J = 7.2Hz, H-Cf), 7.65-7.75 (2H, m, H-Cb Ar), 7.77-7.85 (2H, m, H-Ca Ar). 1-bromo-4-N-phthalimido-2-butanone (C) 4-Phthalimido-2-butanone (compound B) (14 g, 64 mmol) was dissolved in methylene chloride (105 ml) and methanol (85 ml). A solution of bromine (3.3 ml, 64 mmol) in methanol (20 ml) was added dropwise over a 2 h period. The reaction mixture was allowed to stir overnight, and was then treated with additional bromine (0.8 ml, 15.6 mmol); after 1 h, no starting material was visible by TLC (10:1, chloroform:EtOAc). The reaction mixture was concentrated in vacuo to leave a yellow solid, which was triturated with diethyl ether and dried with nitrogen flow to give compound C as white solid (29). Yield: 65%, m.p 105 °C, (Found: M296, C12H10BrNO3 requires 296), νmax = 3001, 2920, 1708 cm-1, 1HNMR (400 MHz, CDCl3) δ: 3.11 (2H, t, J = 7.2 Hz, H-Cg), 3.92 (2H, s, H-Ch), 4.0 (2H, t, J = 7.2 Hz, H-Cf), 7.70-7.77 (2H, m, H-Cb Ar), 7.80-7.90 (2H, m, H-Ca Ar). Thiobenzamide (E) To a solution of 7.9 g (99 mmol) of 70% sodium hydrosulfide hydrate and 10.1 g (50 mmol) of magnesium chloride hexahydrate in 100 ml of dimethylformamide (DMF) was added 5.15 g (50 mmol) of benzonitrile (compound D) (Fig. 1) in one portion, and the mixture was stirred at room temperature for 90 min. The resulting green solution was poured into 200 ml of water, and the product was extracted with diethyl ether. After evaporation of ether in vacuo, the crude product was suspended in 1N HCl and stirred for 20 min, then filtered and washed with water to give compound E (30). Yield: 82%, m.p. 187 °C, (Found: M137, C7H7NS requires 137), νmax = 3356, 3155, 1624 cm-1,1HNMR (400 MHz, CDCl3) δ: 7.34 (2H, t,J = 7.6 Hz, H-C2, H-C4 Ar), 7.45 (1H, t, J = 7.6 Hz, H-C3 Ar), 7.8 (2H, d, J = 7.6 Hz, H-C1, H-C5 Ar). 2- phenyl - 4 -[(2 - N - phthalimido) ethyl] thiazole (F) 1-Bromo-4-phthalimido-2-butanone (compound C) (5.92 g, 20 mmol) and thiobenzamide (compound E) (5.48 g, 40 mmol), were mixed with n-propanol (100 ml) and concentrated hydrochloric acid (10 ml) and the reaction mixture was heated to reflux for 2 h. After cooling, the precipitate was filtered and washed with n-propanol and then by diethyl ether. The hydrochloride product was obtained as a white solid. The free base, was obtained as follow: the product was mixed with saturated aqueous potassium carbonate solution overnight at room temperature. The solid was filtered, washed with water, diethyl ether and air-dried to leave compound F as a white solid (31). Yield: 55%, m.p 120 °C, (Found: M334, C19H14N2O2S requires 334), νmax = 3116, 2947, 1705 cm-1, 1HNMR (400 MHz, CDCl3) δ: 3.23 (2H, t, J = 6.6 Hz, H-Cg), 4.11 (2H, t, J = 6.6 Hz, H-Cf), 6.99 (1H, s, H-Ce), 7.32-7.38 (3H, m, H-CbAr), 7.68-7.72 (2H, m, H-CdAr), 7.76-7.80 (2H, m, H-CcAr), 7.81-7.85 (2H, m, H-CaAr). 2-phenyl-4-(2-aminoethyl) thiazole (G) Compound F (3.67 g, 11 mmol) was added to a solution of hydrazine in methanol (200 ml, 4.0 M), and the reaction mixture was heated for 0.5 h until it became homogenous. The reaction mixture was then stirred at room temperature for further 2 h. Concentration in vacuo provided a white solid, which was purified by column chromatography (eluent: 89:10:1 chloroform:methanol: concentrated ammonium hydrochloride). The title product was obtained as sticky oil (31). Yield: 32%, (Found: M204, C11H12N2S requires 204), νmax = 3368, 1654 cm-1, 1HNMR (400 MHz, CDCl3) δ: 1.6-1.8 (2H, bs, NH2), 2.93 (2H, t, J = 6.0 Hz, H-Cd), 3.07-3.17 (2H, m, H-Ce), 6.93 (1H, m, H-Cc), 7.36-7.45 (3H, m, H-Cb), 7.88-7.96 (2H, m, H-Ca). N-Acyl 5-nitroanthranilic acid (I) Acyl chloride (0.37 mol) was added dropwise to a mixture of 5-nitroanthranilic acid (compound H) (0.25 mol) (Fig. 1) in dimethyl formamide (125 ml) at such rate that the temperature of the mixture did not rise above 40 °C. The mixture was stirred at room temperature for at least an additional 3 h. Completion of the reaction was determined by TLC and the mixture was poured into water (1 L) and stirred for 1 h. The precipitated product was collected by filtration, washed with cold water and dried under reduced pressure yielding (compound I) (Fig. 1) as a white powder. Yield: 55-70%. 2- substituted - 6 - nitro - 1,3 - benzoxazin - 4- one (J1-J6) Compound I (0.125mol) was dissolved in acetic anhydride (90 ml) and slowly heated to 170-180 °C in a round-bottom flask equipped with a magnetic stirrer bar and a claisen- distillation head. Completion of the reaction was confirmed by TLC (20:1, chloroform:methanol), and the produced acetic acid was distilled under reduced pressure. The residue was then cooled and product was washed by n-hexane to give 3(2-methyl-6-nitro-1,3-benzoxazin-4-one) (compound J) (Fig. 1) as yellow crystals (32). Yield: 65-84%. 6-Nitroderivatives of thiazole containing 4(3H) quinazolinones (K1-K6) To prepare 2-substituted-6-nitro-3-(2-(2-phenylthiazole-4-yl) ethyl) quinazolin-4(3H)-ones, 0.5 mmol of related benzoxazone was refluxed with 1 mmol of amine (compound G) in chloroform (10 ml) for 6-7 h. After completion of the reaction, chloroform was evaporated under reduced pressure and the residue was treated with ethylene glycol (5 ml) and NaOH pellets (0.003 g) in a flask equipped with a claisen-distilation head. The mixture was reheated to 130-140 °C for 5 h. After completion of the reaction, the clear solution was allowed to cool to room temperature and kept overnight to precipitate which was then crystallized from 2-propanol to obtain final products. 2 - ethy l- 6 - nitro- 3 - (2 - (2 - phenylthiazol - 4-yl)ethyl)quinazolin-4(3H)-one (K1) Yield: 45%, m.p 203 °C, (Found: M406, C21H18N4O3S requires 406), νmax = 2997, 2912, 1658, 1535, 1311 cm-1, 1HNMR (400 MHz, CDCl3) δ:1.28 (3H, t, J = 8.0Hz, CH3:R), 2.77 (2H, q, J = 8.0 Hz, CH2:R), 3.22(2H, t, J = 8.0 Hz, H-C10), 4.74(2H, t, J = 8.0 Hz, H-C9), 6.89 (1H, s, H-C12), 7.28-7.40 (3H, m, H-C17, H-C18, H-C19), 7.67 (1H, d, J = 8.0 Hz, H-C8), 7.75-7.83 (2H, m, H-C16, H-C20),8.43 (1H, dd, J = 6.4, J = 2.8, H-C7), 9.07 (1H, d, J = 2.8Hz, H-C5) 6 - nitro - 2 - (4 - nitrophenyl) - 3 - (2 - (2 -phenylthiazol-4-yl)ethyl)quinazolin-4(3H)-one (K2) Yield: 54%, m.p 218 °C (Found: M499, C25H17N5O5S requires 499), νmax = 3105, 2850,1678, 1516, 1334 cm-1, 1HNMR (400 MHz, CDCl3) δ: 3.23 (2H, t, J = 6.4 Hz, H-C10), 4.47 (2H, t, J = 6.8Hz, H-C9), 6.88 (1H, s, H-C12), 7.30-7.50(5H, m, H-C17, H-C18, H-C19, Ph-2H:R), 7.60-7.90 (5H, m, H-C16, H-C20, H-C8, Ph-2H:R), 8.42 (1H, dd, J = 6.4Hz, J = 2.8Hz, H-C7), 9.06(1H, d, J = 2.4 Hz, H-C5) 2 - methyl - 6 - nitro-3 - (2 - (2 - phenylthiazol-4-yl)ethyl)quinazolin-4(3H)-one (K3) Yield: 52%, m.p 197 °C, (Found: M392, C20H16N4O3S requires 392), νmax= 3101, 2924, 1678, 1516, 1334 cm-1,1HNMR (400 MHz, CDCl3) δ:2.51 (3H, S, CH3:R), 3.23 (2H, t, J = 8.0 Hz, H -C10), 4.46 (2H, t, J = 8.0 Hz, H-C9), 6.88 (1H, s, H-C12), 7.30-7.42 (3H, m, H-C17, H-C18, H-C19), 7.62 (1H, d, J = 8.0 Hz, H-C8), 7.73-7.87 (2H, m, H-C16, H-C20), 8.42 (1H, dd, J = 8.0 Hz, J = 2.8 Hz, H-C7), 9.06 (1H, d, J = 2.4 Hz, H-C5) 6-nitro-3-(2-(2-phenylthiazole-4-yl)ethyl)-2-propylquinazolin-4(3H)-one (K4) Yield: 75%, m.p 215 °C, (Found: M420, C22H20N4O3S requires 420), νmax = 3101, 2870, 1689, 1512, 1330 cm-1, 1HNMR (400 MHz, CDCl3) δ: 0.95 (3H, t, J = 8.0 Hz, CH3:R), 1.74 (2H, hex, J = 8.0 Hz, CH2:R), 2.68 (2H, t, J = 8.0Hz, CH2:R), 3.22 (2H, t, J = 8.0 Hz, H-C10), 4.74 (2H, t, J = 8.0 Hz, H-C9), 6.88 (1H, s, H-C12), 7.30-7.39 (3H, m, H-C17, H-C18, H-C19), 7.64 (1H, d, J = 8.0Hz, H-C8), 7.75-7.85 (2H, m, H-C16, H-C20), 8.42 (1H, dd, J = 8.0, J = 2.4, H-C7), 9.06 (1H, d, J = 2.4Hz, H-C5) 6 - nitro - 2 - phenyl - 3 - (2-(2-phenylthiazole-4-yl)ethyl)quinazolin-4(3H)-one (K5) Yield: 49%, m.p 187 °C, (Found: M454, C25H18N4O3S requires 454), νmax = 3101, 1689,1504, 1315 cm-1,1HNMR (400 MHz, CDCl3) δ: 3.26 (2H, t, J = 6.0 Hz, H-C10), 4.44 (2H, t, J = 6.0Hz, H-C9), 6.84 (1H, s, H-C12), 7.30-7.45 (4H, m, H-C17, H-C18, H-C19, Ph-1H:R), 7.60-8.05 (7H, m, H-C16, H-C20, H-C8, Ph-4H:R), 8.43 (1H, dd, J = 6.4Hz, J = 2.8Hz, H-C7), 9.11(1H, d, J = 2.4 Hz, H-C5) 2 - (4 - chlorophenyl) – 6 – nitro – 3 - (2 - (2 -phenylthiazole-4-yl)ethyl)quinazolin-4(3H)-one (K6) Yield: 61%, m.p 210 °C, (Found: M488, C25H17ClN4O3S requires 488), νmax = 3101, 2927, 1681, 1516, 1338 cm-1, 1HNMR (400 MHz, CDCl3) δ:3.03 (2H, t, J = 6.4 Hz, H-C10), 4.44 (2H, t, J = 6.8Hz, H-C9), 6.96 (1H, s, H-C12), 7.30 (2H, d, J = 8.4 Hz, H-C16, H-C20), 7.32-7.37 (4H, m, H-C17, H-C19, Ph-2H:R), 7.38-7.40 (2H, m, H-C18, H-C8), 7.70 (1H, dd, J = 6.4Hz, J = 2.8 Hz, H-C7), 7.84-7.87 (2H, m, Ph-2H:R),9.06 (1H, d, J = 2.4 Hz, H-C5). Antiproliferative effects of the derivatives MTT assay results for evaluation of cytotoxic effects of the compounds are shown in Figs. 2, 3, and 4. Their IC50 (μM) values are also listed in Table 1.
Fig. 2

The percentage of cytotoxicity versus concentration by MTT exclusion on MCF-7 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.

Fig. 3

The percentage of cytotoxicity versus concentration by MTT exclusion on HT-29 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.

Fig. 4

The percentage of cytotoxicity versus concentration by MTT exclusion on PC-3 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments.

Table 1

The IC50 (μM) of tested compounds against MCF-7, HT-29, and PC-3 cancer cell lines

The percentage of cytotoxicity versus concentration by MTT exclusion on MCF-7 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments. The percentage of cytotoxicity versus concentration by MTT exclusion on HT-29 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments. The percentage of cytotoxicity versus concentration by MTT exclusion on PC-3 cancer cell line. IC50 value was obtained by plotting the percentage of proliferation values versus drug concentrations. Data are expressed as the mean ± SEM of three separate experiments. The IC50 (μM) of tested compounds against MCF-7, HT-29, and PC-3 cancer cell lines

DISCUSSION

The synthesized 4(3H) quinazolinones in this study contained 4-ethyl-2-phenylthiazole group on position 3 of quinazolinone structure. For preparation of these quinazolinones, a primary amine containing thiazole (compound G) (Fig. 1) was synthesized. The most practical method to prepare thiazoles is Hantzsch reaction which involves the condensation of α-haloketones and thiourea or thioamides in refluxing alcohol. Phthalimide as an NH2-synthon was used here for the preparation of the amine. Application of phthalimide in Gabriel synthesis for preparation of primary amines is well documented. After alkylation, the resulting alkyl phthalimide is reacted with hydrazine. The desired primary amine could be generated by reacting with hydrazine hydrate. Consequently phthalazine as a stable cyclic product is formed and precipitated (Fig. 5). The reaction of 2-phenyl-4-(2-aminoethyl) thiazole (compound G) with different benzoxazinones resulted in the production of new 4(3H)quinazolinones (Fig. 1).
Fig. 5

Amine generation mechanism.

Amine generation mechanism.

CONCLUSION

In this study, quinazolinones as biologically active compounds were conjugated with another well-known moiety (thiazole ring) in a multi-step reaction procedure to produce interesting novel compounds. All synthesized compounds were tested for their cytotoxic effects on three cell lines including MCF-7, HT-29, and PC-3 of which quinazolinones K1-K6 and three intermediates, compound C, F, and G, k5 and k6 showed highest cytotoxic activities against PC3 cell line. K6 and compound C were most active against MCF-7 and K6 showed best cytotoxicity on HT-29 cell line.
  21 in total

1.  Synthesis, antibacterial, antifungal and anti-HIV activities of Schiff and Mannich bases derived from isatin derivatives and N-[4-(4'-chlorophenyl)thiazol-2-yl] thiosemicarbazide.

Authors:  S N Pandeya; D Sriram; G Nath; E DeClercq
Journal:  Eur J Pharm Sci       Date:  1999-10       Impact factor: 4.384

2.  Synthesis and biological properties of 4-(3H)-quinazolone derivatives.

Authors:  Anjani K Tiwari; Vinay Kumar Singh; Aruna Bajpai; Gauri Shukla; Sweta Singh; Anil K Mishra
Journal:  Eur J Med Chem       Date:  2007-01-20       Impact factor: 6.514

3.  Non-classical antifolates. Part 2: synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones.

Authors:  Fatmah A M Al-Omary; Laila A Abou-Zeid; Mahmoud N Nagi; El-Sayed E Habib; Alaa A-M Abdel-Aziz; Adel S El-Azab; Sami G Abdel-Hamide; Mohamed A Al-Omar; Abdulrahman M Al-Obaid; Hussein I El-Subbagh
Journal:  Bioorg Med Chem       Date:  2010-03-12       Impact factor: 3.641

4.  Synthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-one.

Authors:  S N Pandeya; D Sriram; G Nath; E De Clercq
Journal:  Pharm Acta Helv       Date:  1999-12

5.  Synthesis and in vitro cytotoxic evaluation of some thiazolylbenzimidazole derivatives.

Authors:  Yu Luo; Feng Xiao; Shijing Qian; Wei Lu; Bo Yang
Journal:  Eur J Med Chem       Date:  2010-11-27       Impact factor: 6.514

6.  3H-Quinazolin-4-ones as a new calcilytic template for the potential treatment of osteoporosis.

Authors:  Irina Shcherbakova; Manuel F Balandrin; John Fox; Anjan Ghatak; William L Heaton; Rebecca L Conklin
Journal:  Bioorg Med Chem Lett       Date:  2005-03-15       Impact factor: 2.823

7.  Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs.

Authors:  Abdulrahman M Al-Obaid; Sami G Abdel-Hamide; Hassan A El-Kashef; Alaa A-M Abdel-Aziz; Adel S El-Azab; Hamad A Al-Khamees; Hussein I El-Subbagh
Journal:  Eur J Med Chem       Date:  2008-09-23       Impact factor: 6.514

8.  3-(4-(Benzo[d]thiazol-2-yl)-1-phenyl-1H-pyrazol-3-yl) phenyl acetate induced Hep G2 cell apoptosis through a ROS-mediated pathway.

Authors:  Jianyong Li; Zhijun Xu; Mengyao Tan; Weike Su; Xing-guo Gong
Journal:  Chem Biol Interact       Date:  2009-12-16       Impact factor: 5.192

9.  Synthesis and antibacterial activity of some new thiazole and thiophene derivatives.

Authors:  A M Khalil; M A Berghot; M A Gouda
Journal:  Eur J Med Chem       Date:  2009-06-13       Impact factor: 6.514

10.  The antihyperlipidemic activities of 4(3H) quinazolinone and two halogenated derivatives in rats.

Authors:  Fawzia M Refaie; Amr Y Esmat; Soad M Abdel Gawad; Aida M Ibrahim; Mona A Mohamed
Journal:  Lipids Health Dis       Date:  2005-10-04       Impact factor: 3.876

View more
  7 in total

1.  Synthesis, characterization, cytotoxic screening, and density functional theory studies of new derivatives of quinazolin-4(3H)-one Schiff bases.

Authors:  Rezvan Rezaee Nasab; Farshid Hassanzadeh; Ghadam Ali Khodarahmi; Mahmoud Mirzaei; Mahboubeh Rostami; Ali Jahanian-Najaf Abadi
Journal:  Res Pharm Sci       Date:  2017-12

2.  Synthesis and cytotoxic effect of a few N-heteroaryl enamino amides and dihydropyrimidinethiones on AGS and MCF-7 human cancer cell lines.

Authors:  Sajjad Tavangar; Shahab Bohlooli; Nima Razzaghi-Asl
Journal:  Res Pharm Sci       Date:  2020-05-11

3.  Synthesis and cytotoxic evaluation of some novel 3-[2-(2-phenyl-thiazol-4-yl)-ethyl]-3H-pyrido[2,3-d]pyrimidin-4-one derivatives.

Authors:  Marzieh Rahmani Khajouei; Ghadamali Khodarahmi; Aram Ghaderi
Journal:  Res Pharm Sci       Date:  2021-08-19

4.  Design, synthesis, cytotoxicity evaluation and docking studies of 1,2,4-triazine derivatives bearing different arylidene-hydrazinyl moieties as potential mTOR inhibitors.

Authors:  Sara Ranjbar; Najmeh Edraki; Mahsima Khoshneviszadeh; Alireza Foroumadi; Ramin Miri; Mehdi Khoshneviszadeh
Journal:  Res Pharm Sci       Date:  2018-02

5.  Synthesis and cytotoxic evaluation of some new 3-(2-(2-phenylthiazol-4-yl) ethyl)-quinazolin-4(3H) one derivatives with potential anticancer effects.

Authors:  Leila Hosseinzadeh; Alireza Aliabadi; Mohsen Rahnama; Hamid Mir Mohammad Sadeghi; Marzieh Rahmani Khajouei
Journal:  Res Pharm Sci       Date:  2017-08

6.  Synthesis and cytotoxic evaluation of some derivatives of triazole-quinazolinone hybrids.

Authors:  Farshid Hassanzadeh; Hojjat Sadeghi-Aliabadi; Shadan Nikooei; Elham Jafari; Golnaz Vaseghi
Journal:  Res Pharm Sci       Date:  2019-03-08

7.  Cytotoxicity and pro-apoptosis activity of synthetic 1,3-thiazole incorporated phthalimide derivatives on cancer cells.

Authors:  Omid Tavallaei; Milad Heidarian; Marzieh Marzbany; Alireza Aliabadi
Journal:  Iran J Basic Med Sci       Date:  2021-05       Impact factor: 2.699

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.